作者
Benedikt S. Saller,Svenja Wöhrle,Larissa Fischer,Clara Dufossez,Isabella L. Ingerl,Susanne Kessler,Maria Mateo Tortola,Oliver Gorka,Felix Lange,Yurong Cheng,Emilia Neuwirt,Adinarayana Marada,Christoph Koentges,Christian Urban,Philipp Aktories,Peter Reuther,Sebastian Giese,Susanne Kirschnek,Christine Mayer,Johannes Pilic,Hugo Falquez-Medina,Aline Oelgeklaus,Veerasikku Gopal Deepagan,Farzaneh Shojaee,Julia A. Zimmermann,Dominik Weber,Yi-Heng Tai,Anna Crois,Kevin Ciminski,Rémi Peyronnet,Klaus Brandenburg,Gang Wu,Ralf Baumeister,Thomas Heimbucher,Marta Rizzi,Dietmar Riedel,Martin Helmstädter,Joerg M. Buescher,Konstantin Neumann,Thomas Misgeld,Martin Kerschensteiner,Peter Walentek,Clemens Kreutz,Ulrich Maurer,Angelika S. Rambold,James E. Vince,Frank Edlich,Roland Malli,Georg Häcker,Katrin Kierdorf,Chris Meisinger,Anna Köttgen,Stefan Jakobs,Alexander N.R. Weber,Martin Schwemmle,Christina J. Groß,Olaf Groß
摘要
How mitochondria reconcile roles in functionally divergent cell death pathways of apoptosis and NLRP3 inflammasome-mediated pyroptosis remains elusive, as is their precise role in NLRP3 activation and the evolutionarily conserved physiological function of NLRP3. Here, we have shown that when cells were challenged simultaneously, apoptosis was inhibited and NLRP3 activation prevailed. Apoptosis inhibition by structurally diverse NLRP3 activators, including nigericin, imiquimod, extracellular ATP, particles, and viruses, was not a consequence of inflammasome activation but rather of their effects on mitochondria. NLRP3 activators turned out as oxidative phosphorylation (OXPHOS) inhibitors, which we found to disrupt mitochondrial cristae architecture, leading to trapping of cytochrome c. Although this effect was alone not sufficient for NLRP3 activation, OXPHOS inhibitors became triggers of NLRP3 when combined with resiquimod or Yoda-1, suggesting that NLRP3 activation requires two simultaneous cellular signals, one of mitochondrial origin. Therefore, OXPHOS and apoptosis inhibition by NLRP3 activators provide stringency in cell death decisions.